cetuximab
Sign in to saveAlso known as IMC-C225, C225, IMC-225, Anti EGFR
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 460026782
- Drug.type
- mab
- Drug.image
- Cetuximab.png
- Drug.mab_type
- mab
- Drug.source
- xi/o
- Drug.target
- EGF receptor
- Drug.tradename
- Erbitux
- Drug.DailyMedID
- Cetuximab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FE01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Research
9,866 papers- Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.Cell death & disease · 2021
- [Cetuximab].Gan to kagaku ryoho. Cancer & chemotherapy · 2007
- Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis.Oncology · 2020
- Cetuximab-induced bullous pemphigoid.Italian journal of dermatology and venereology · 2023
- Cetuximab for treating non-small cell lung cancer.Expert opinion on biological therapy · 2018
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 7 more facts
- medical condition treated
- oropharynx cancer
- World Health Organisation international non-proprietary name
- cetuximab
- Commons category
- Cetuximab
- subject has role
- monoclonal antibody
- route of administration
- intravenous infusion and defusion
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
Sources (6)
via Wikidata · CC0
~7 min read
Encyclopedic overview
16 sectionsContents
- Medical uses
- Head and neck cancer
- Colorectal cancer
- Side effects
- Alpha-gal allergy
- Mechanism of action
- KRAS Testing
- History
- Society and culture
- Manufacture
- Distribution
- Economics
- Biosimilars
- Insider trading
- Research
- References
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
Cetuximab was approved for medical use in the United States in 2004.
Excerpted from Wikipedia’s “cetuximab” article, available under the CC BY-SA 4.0 licence.